*Estimated payments are calculated by Cars.com and are for informational purposes only. We’ve estimated your taxes based on your provided ZIP code. These estimates do not include title ...

Over the past couple of weeks, Angelina Jolie has been all over the news as one of the two warring parties in Hollywood’s most gilded divorce case: her eight-year battle with Brad Pitt over the ...

Somer G. Anderson is CPA, doctor of accounting, and an accounting and finance professor who has been working in the accounting and finance industries for more than 20 years. Her expertise ...

Update, Jan. 23: Multiple sources tell CBS News the Trump administration is expected to name an acting director from outside the CDC. Read the latest here. The Centers for Disease Control and ...

Sanofi and Regeneron's Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising the hope of a new treatment option for the rare and highly debilitating skin ...

J.B. Maverick is an active trader, commodity futures broker, and stock market analyst 17+ years of experience, in addition to 10+ years of experience as a finance writer and book editor. Suzanne ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.

Jha is the dean of the Brown University School of Public Health and former White House Covid-19 response coordinator. The likely next secretary of state, Sen. Marco Rubio, once said of the World ...

According to People, Jolie, 49, is "heartbroken" by the devastation caused by the historic blazes and is determined to do all she can to assist anyone who has been affected by the fires, including ...

The use of Sanofi’s Dupixent in atopic dermatitis has set a high benchmark for competitors within the space. Credit: marishkaSm via Shutterstock. Sanofi’s participation at the JP Morgan 43rd Annual ...

Sanofi’s chief executive Paul Hudson discussed the success of Dupixent (dupilumab)and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...